ARNA prbly has a better chance based on what happened at todays panel. I think the three concerns are efficacy, valvulopathy and the fact that the panel has been convened on a date about a month before PDUFA. The latter point suggests that at the very least there could be a delay.
Market Data 
Markets 
AI
